Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- CLINICAL LYMPHOMA MYELOMA & LEUKEMIA19(3) · pp.149 · 2019
- 피인용
- Web of Science 9Scopus 9
- FWCI (Scopus)
- 0.19
- JCR IF
- JCR 2018 2.274
- ISSN
- 2152-2650
저자
- 박성우제1저자Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea
- Jo, Jae-CheolDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
- Do, Young RokDivision of Hematology-Oncology, Keimyung University, School of Medicine, Keimyung University Hospital, Daegu, South Korea
- Yang, Deok-HwanDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea
- Lim, Sung-NamDepartment of internal medicine, Inje university college of medicine, Haeundae Paik hospital, Busan, South Korea
- Lee, Won-SikDepartment of Internal Medicine, Division of Hemato-Oncology, Inje University Busan Paik Hospital, Busan, South Korea
- Kim, Won SeogDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Lee, Ho SupDivision of Hematology-Oncology, Kosin University Gospel Hospital, Busan, South Korea
- Hong, Dae-SikDepartment of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Bucheon, South Korea
- Kim, Hyo JungDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea
- 신호진교신저자Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea
초록
We assessed 53 patients aged >= 65 years in South Korea to evaluate the efficacy and toxicity of reduced-dose (RD) rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy for elderly patients with diffuse large B-cell lymphoma. RD-R-CHOP chemotherapy showed comparable survival benefits compared to those who received previous RD-R-CHOP-like chemotherapy. Introduction: Elderly patients are more prone to encounter some adverse factors when they receive chemotherapy compared to younger patients. Addition of rituximab to a reduced dose (RD) of cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy might improve patient outcomes with an improved toxicity profile when provided to elderly patients with diffuse large B-cell lymphoma. Patients and Methods: A total of 53 patients aged >= 65 years with diffuse large B-cell lymphoma diagnosed between August 2012 and December 2014 were enrolled onto this study. RD-R-CHOP regimen consisted of rituximab at 375 mg/m(2), cyclophosphamide at 600 mg/m(2), doxorubicin at 30 mg/m(2), and vincristine at 1 mg on day 1 of each cycle and 40 mg of prednisone on days 1 to 5. Patients received granulocyte colony-stimulating factor if they experienced grade 3/4 neutropenia or febrile neutropenia during any cycle. Results: The median follow-up duration was 18 months (range, 1-44 months). Complete response and overall response rates were 64.1% and 81.1%, respectively. Three-year event-free and overall survival rates were 45.7% +/- 8.4% and 62.7% +/- 8.1%, respectively. Grade 3/4 neutropenia occurred in 20 patients (37.7%), while febrile neutropenia occurred in 7 patients (20.7%). Conclusion: Outcomes of RD-R-CHOP chemotherapy were comparable to those of standard-dose R-CHOP or previous dose-adjusted R-CHOP chemotherapy. In the future, strategies such as tailored therapy based on geriatric assessment results are needed to determine the chemotherapeutic dosage.
키워드
Chemotherapeutic dosageLymphoproliferative disordersOlder patientsPrognostic factorsToxicityNON-HODGKINS-LYMPHOMACOLONY-STIMULATING FACTORPLUS RITUXIMABFEBRILE NEUTROPENIARESPONSE CRITERIAIMPACTRISKCYCLOPHOSPHAMIDEVINCRISTINEDOXORUBICIN
식별자
- Scopus EID
- 2-s2.0-85058694440
- WoS UID
- 000459339200009



로그인
연구물 목록으로